Lumbrokinase attenuates diabetic nephropathy through regulating extracellular matrix degradation in Streptozotocin-induced diabetic rats

Diabetes Research and Clinical Practice

Volumn 100, Issue 1, 2013, Pages 85-95

  Sun, Huili ^a,b   Ge, Na ^a   Shao, Mumin ^a   Cheng, Xiaoyan ^a   Li, Yue ^b   Li, Shunmin ^a   Shen, Jiangang ^a,b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Collagen IV; Diabetic nephropathy; Lumbrokinase; MMP 2; MMP 9

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; COLLAGEN TYPE 4; CREATININE; GELATINASE A; GELATINASE B; LUMBROKINASE; PERINDOPRIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME REGULATION; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX DEGRADATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY INJURY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SCORING SYSTEM; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION;

EID: 84876700560     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.01.012     Document Type: Article

References (48)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986.
2. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 1994, 5(5):1165-1172.
3. Miner J.H. Renal basement membrane components. Kidney Int 1999, 56(6):2016-2024.
4. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990, 6(4):121-125.
5. Davies M., Coles G.A., Thomas G.J., Martin J., Lovett D.H. Proteinases and the glomerulus: their role in glomerular diseases. Klin Wochenschr 1990, 68(22):1145-1149.
6. Nyska M., McCabe C., Linge K., Laing P., Klenerman L. Effect of the shoe on plantar foot pressures. Acta Orthop Scand 1995, 66(1):53-56.
7. McLennan S.V., Fisher E.J., Yue D.K., Turtle J.R. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 1994, 43(8):1041-1045.
8. McLennan S.V., Kelly D.J., Cox A.J., Cao Z., Lyons J.G., Yue D.K., et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002, 45(2):268-275.
9. Amri K., Freund N., Vilar J., Merlet-Benichou C., Lelievre-Pegorier M. Adverse effects of hyperglycemia on kidney development in rats: in vivo and in vitro studies. Diabetes 1999, 48(11):2240-2245.
10. Duong Van Huyen J.P., Viltard M., Nehiri T., Freund N., Belair M.F., Martinerie C., et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 is altered during nephrogenesis in fetuses from diabetic rats. Lab Invest 2007, 87(7):680-689.
11. Mihara H., Sumi H., Akazawa K., Yoneta T., Mizumoto H. Fibrinolytic enzyme extracted from earthworm. Thromb Haemost 1983, 50(1):258.
12. Cooper E.L. CAM, eCAM, bioprospecting: the 21st century pyramid. Evid Based Complement Altern Med 2005, 2(2):125-127.
13. Balamurugan M., Parthasarathi K., Cooper E.L., Ranganathan L.S. Earthworm paste (Lampito mauritii, Kinberg) alters inflammatory, oxidative, haematological and serum biochemical indices of inflamed rat. Eur Rev Med Pharmacol Sci 2007, 11(2):77-90.
14. Prakash M., Balamurugan M., Parthasarathi K., Gunasekaran G., Cooper E.L., Ranganathan L.S. Anti-ulceral and anti-oxidative properties of "earthworm paste" of Lampito mauritii (Kinberg) on Rattus Norvegicus. Eur Rev Med Pharmacol Sci 2007, 11(1):9-15.
15. Ismail S.A., Pulandiran K., yegnanarayan R. Anti-inflammatory activity of earthworm extracts. Soil Biol Biochem 1992, 24(12):1253-1254.
16. Hu R., Zhang S., Liang H., Li N., Tu C. Codon optimization, expression, and characterization of recombinant lumbrokinase in goat milk. Protein Expr Purif 2004, 37(1):83-88.
17. Hwang C.M., Kim D.I., Huh S.H., Min B.G., Park J.H., Han J.S., et al. In vivo evaluation of lumbrokinase, a fibrinolytic enzyme extracted from Lumbricus rubellus, in a prosthetic vascular graft. J Cardiovasc Surg (Torino) 2002, 43(6):891-894.
18. Huang Z.D., Li Z.W., Zhang W.X. Lumbrokinase in treating cerebral infarction. Chin J New Drugs Clin Remedies 2000, 6(19):453-455.
19. Liao R.H. Analytical report of treating 30 patients of ischemic cerebrovascular disease with anford lumbrokinase and nimodipine. Strait Pharm J 1997, 9(3):25-26.
20. Pang S.Q., Ding M.C., Xie S.P. A clinical study of therapeutic effectiveness in treating ischemic cerebrovascular disease with Lumbrokinase (Boluoke). Chin J Neurol Psychiatry 1993, 26(4):229-232.
21. Nakajima N., Sugimoto M., Ishihara K., Nakamura K., Hamada H. Further characterization of earthworm serine proteases: cleavage specificity against peptide substrates and on autolysis. Biosci Biotechnol Biochem 1999, 63(11):2031-2033.
22. Park Y., Ryu E., Kim H., Jeong J., Kim J., Shim J., et al. Characterization of antithrombotic activity of lumbrokinase-immobilized polyurethane valves in the total artificial heart. Artif Organs 1999, 23(2):210-214.
23. Mihara H., Yineta T., Sumi H., Soeda M., Maruyama M. A possibility of earthworm powder as therapeutic agent for thrombosis. Thromb Haemost 1989, 62(1):545-549.
24. Ji H., Wang L., Bi H., Sun L., Cai B., Wang Y., et al. Mechanisms of lumbrokinase in protection of cerebral ischemia. Eur J Pharmacol 2008, 590(1-3):281-289.
25. Matsuba S. Complementary and alternative approaches to biomedicine. Evid Based Complement Altern Med 2004, 1:345-348.
26. Sun H.L., Sun L., Li Y.Y., Shao M.M., Cheng X.Y., Ge N., et al. ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. Exp Clin Endocrinol Diab 2009, 117(7):336-344.
27. Saito T., Sumithran E., Glasgow E.F., Atkins R.C. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987, 32(5):691-699.
28. Klahr S., Schreiner G., Ichikawa I. The progression of renal disease. N Engl J Med 1988, 318(25):1657-1666.
29. Liotta L.A., Goldfarb R.H., Terranova V.P. Cleavage of laminin by thrombin and plasmin: alpha thrombin selectively cleaves the beta chain of laminin. Thromb Res 1981, 21(6):663-673.
30. Catania J.M., Chen G., Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007, 292(3):F905-F911.
31. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69(3):562-573.
32. McLennan S.V., Fisher E., Martell S.Y., Death A.K., Williams P.F., Lyons J.G., et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int 2000, 58(Suppl. 77):S81-S87.
33. Han S.Y., Jee Y.H., Han K.H., Kang Y.S., Kim H.K., Han J.Y., et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006, 21(9):2406-2416.
34. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69(2):213-217.
35. Nath K.A. The tubulointerstitium in progressive renal disease. Kidney Int 1998, 54(3):992-994.
36. Kim Y., Kleppel M.M., Butkowski R., Mauer S.M., Wieslander J., Michael A.F. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol 1991, 138(2):413-420.
37. Zhu D., Kim Y., Steffes M.W., Groppoli T.J., Butkowski R.J., Mauer S.M. Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry. Kidney Int 1994, 45(2):425-433.
38. Liu X., Luo F., Pan K., Wu W., Chen H. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biol 2007, 8:1.
39. Sato H., Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 1996, 119(2):209-215.
40. Cho I.H., Choi E.S., Lim H.G., Lee H.H. Purification and characterization of six fibrinolytic serine-proteases from earthworm Lumbricus rubellus. J Biochem Mol Biol 2004, 37(2):199-205.
41. Zhao J., Li L., Wu C., He R.Q. Hydrolysis of fibrinogen and plasminogen by immobilized earthworm fibrinolytic enzyme II from Eisenia fetida. Int J Biol Macromol 2003, 32(3-5):165-171.
42. Hoylaerts M., Rijken D.C., Lijnen H.R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982, 257(6):2912-2919.
43. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986, 261(8):3486-3489.
44. Ichinose A., Kisiel W., Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett 1984, 175(2):412-418.
45. Baricos W.H., Cortez S.L., el-Dahr S.S., Schnaper H.W. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995, 47(4):1039-1047.
46. Desrochers P.E., Jeffrey J.J., Weiss S.J. Interstitial collagenase (matrix metalloproteinase-1) expresses serpinase activity. J Clin Invest 1991, 87(6):2258-2265.
47. van der Zijl N.J., Hanemaaijer R., Tushuizen M.E., Schindhelm R.K., Boerop J., Rustemeijer C., et al. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy?. Clin Biochem 2010, 43(7-8):635-639.
48. Chung A.W., Yang H.H., Sigrist M.K., Brin G., Chum E., Gourlay W.A., et al. Matrix metalloproteinase-2 and -9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease. Cardiovasc Res 2009, 84(3):494-504.